Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $58.65, for a total value of $1,466,250.00. Following the sale, the chief executive officer directly owned 1,148,095 shares of the company’s stock, valued at approximately $67,335,771.75. This represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.

Liquidia Stock Performance

NASDAQ LQDA opened at $61.77 on Thursday. The stock has a 50-day simple moving average of $41.15 and a two-hundred day simple moving average of $36.81. The firm has a market capitalization of $5.49 billion, a P/E ratio of 441.25 and a beta of 0.41. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $62.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently made changes to their positions in the stock. Farallon Capital Management LLC grew its position in shares of Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after purchasing an additional 90,400 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after purchasing an additional 52,671 shares in the last quarter. Opaleye Management Inc. grew its position in shares of Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares in the last quarter. Bank of America Corp DE lifted its holdings in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the last quarter. Finally, Caprock Group LLC lifted its holdings in Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after acquiring an additional 151,832 shares during the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LQDA. Needham & Company LLC boosted their target price on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Oppenheimer lifted their price objective on Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a report on Thursday, March 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. BTIG Research boosted their price objective on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, HC Wainwright boosted their price objective on Liquidia from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).